Ambrisentan effective in portopulmonary hypertension.

One of the complications of the end stage liver disease is portopulmonary hypertension which is estimated to occur in 4 to 10% of people with liver disease. When left untreated only 14% survive beyond 5 years whereas with appropriate medical therapy, the five year survival rate improves to 68% The medical therapy for portopulmonary hypertension includes prostanoids like iv epoprostenol, phosphodiesterase inhibitor like sildenafil and endothelin receptor antagonists like bosentan. Some of the...

More Articles